Treatment of chronic meningitis depends on the underlying cause. Once a specific cause has been established, appropriate targeted therapy is initiated. When the cause is unknown, a decision must be made whether to employ empiric therapy while the diagnostic evaluation is ongoing. This decision is based on three factors: 1) the clinical status of the patient; 2) the most likely cause based on demographic, historical, examination, and initial laboratory data; and 3) the risk-to-benefit ratio of the proposed treatment regimen. Initial efforts focus on deciding whether the meningitis is infectious or noninfectious. When a decision is made to start empiric therapy, antituberculous treatment is generally given for several weeks to judge therapeutic response. Patients who do not respond to antituberculous therapy are next treated with broad-spectrum antibiotics for unusual bacterial pathogens such as Actinomyces (penicillin), the Lyme disease spirochete Borrelia burgdorferi (ceftriaxone), Brucella (doxycycline plus rifampin), or Francisella tularensis (streptomycin plus gentamicin). Antifungal therapy is generally reserved for patients who are at particular risk for mycotic infection (owing to underlying immunosuppression or an extraneural infection site). Finally, empiric glucocorticoids are generally reserved for patients with consistently negative culture results and a probable noninfectious cause.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Tandon PN: Tuberculous meningitis (cranial and spinal). In Infections of the Nervous System, Part 1 (Handbook of Clinical Neurology, vol 23). Edited by Vinken PJ, Bruyn GW. Amsterdam: Elsevier/North Holland; 1978:195–262.Google Scholar
- 4.Anderson NE, Willoughby EW, Synek BJL: Leptomeningeal and brain biopsy in chronic meningitis. Aust NZ J Med 1995, 25:703–706.Google Scholar
- 8.Leenders ACAP, Reiss P, Portegies P, et al.: Liposomal amphotericin B (Ambisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997, 11:1463–1471. This randomized study of HIV-infected patients with cryptococcal meningitis documented faster CSF sterilization and less toxicity with a lipid form of amphotericin B. It did not, however, show greater clinical efficacy.PubMedCrossRefGoogle Scholar
- 9.Saag MS, Cloud GA, Graybill JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:291–296. This randomized study found fluconazole (200 mg/d) to be superior to itraconazole as maintenance therapy for cryptococcal meningitis in HIV-positive patients. Lack of addition of flucytosine to amphotericin B in the first 2 weeks of treatment was the major factor associated with relapse.PubMedGoogle Scholar
- 14.Charleston AJ, Anderson NE, Willoughby EW: Idiopathic steroid-responsive chronic lymphocytic meningitis —clinical features and long-term outcome in 17 patients. Aust NZ J Med 1998, 28:784–789.Google Scholar
- 15.Jacobs RA, Guglielmo BJ: Anti-infective chemotherapeutic and antibiotic agents. In Current Medical Diagnosis and Treatment, edn 39. Edited by Tierney LM, McPhee SJ, Papadakis MA. New York: Lange Medical Books/McGraw Hill; 2000:1476–1519. Ani excellent brief review of antimicrobials.Google Scholar
- 16.Van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15–21. In this controlled trial, induction therapy for 2 weeks with amphotericin B plus flucytosine was superior to amphotericin B alone.PubMedCrossRefGoogle Scholar